Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @formycon
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @formycon
-
#Biosimilars offer an opportunity to help reduce total biologic drug spend. They could save between $54 to $250 bn over their first 10 years on the market. According to a recent estimate, there are more than 1000 biosimilars in any stage of the pipelinehttps://www.pharmacytimes.com/news/overview-of-the-biosimilar-landscape …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon proslijedio/la je Tweet
The
#biosimilars market is expected to expand in the coming years as many reference drugs will soon lose patent exclusivity. By 2026,#biosimilars could save as much as $150 billion according to a recent article in@FiercePharma. More: http://bit.ly/2NoL12k pic.twitter.com/DOEZ0yQLUQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The next decade of biologics facing loss of exclusivity will define the opportunities available to
#biosimilar manufacturers.https://twitter.com/IQVIA_GMI/status/1219273416018223105 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon proslijedio/la je Tweet
Biosimilar Uptake in Europe: Big Challenges; Bigger Rewards. Our colleague & Chair of the Biosimilar medicines group Isabell Remus outlines her vision for the future of
#biosimilar medicines in#Europe (via PharmaBoardroom)#BIOS20 https://pharmaboardroom.com/articles/biosimilar-uptake-in-europe-big-challenges-bigger-rewards/ …pic.twitter.com/Z3YaiV82BF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Who Are the Key
#Lucentis Biosimilar Players to Watch? Good coverage on main players for#Ranibizumab#Biosimilar.@StanMehr@Formycon@Coherus_Biohttps://biosimilarsrr.com/2020/01/16/who-are-the-key-lucentis-biosimilar-players-to-watch/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Top product forecasts for 2020: Global Sales for
#Stelara and#Eylea are estimated to be more than USD 7 billion each. An enormous target market for#biosimilars https://www.nature.com/articles/d41573-020-00011-5 …https://twitter.com/NatRevDrugDisc/status/1217456459463766017 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon proslijedio/la je Tweet
Great piece highlighting the FDA CDER team approving a record number of biosimilars in 2019, increasing choice for patients across the U.S. I’m looking forward to advancing biosimilars even further with
@SecAzar and@POTUS in 2020. http://bit.ly/306pIYj pic.twitter.com/eL4TisKXBZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon proslijedio/la je Tweet
Heute im
#handelsblatt: Dieses Jahr verlieren in Deutschland Medikamente mit einem Gesamtumsatz von knapp 700 Millionen Euro ihren Patentschutz - größtenteils Biopharmazeutika.#Biosimilars haben ein riesiges Sparpotential fürs Gesundheitswesen!https://www.handelsblatt.com/unternehmen/industrie/biotech-nachahmermedizin-patent-laeuft-aus-roche-krebsmedikament-bekommt-konkurrenz/25391656.html?ticket=ST-50122029-Lu9qqSU5c5mGLEN4lFIC-ap4 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
In Deutschland etablieren sich
#Biosimilars zu einer festen Größe im#Gesundheitssystem. Der durchschnittliche#Versorgungsanteil verfügbarer Biosimilars beträgt bereits 54,4%.https://probiosimilars.de/presse/versorgung/grafik-des-monats-dezember-4/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Von den Maßnahmen des bay.
#Pharmagipfels sollen auch#Biosimilars profitieren. Der bay.#Wirtschaftsminister spricht sich für Regularien für Generika und Biosimilars aus um das Potenzial für eine nachhaltige#Versorgung weiter auszuschöpfen.@StMWi_Bayernhttps://www.stmwi.bayern.de/presse/pressemeldungen/pressemeldung/pm/42969/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon proslijedio/la je Tweet
Deutschlands erfolgreichster Biotech-Investor Thomas Strüngmann kritisiert die Abhängigkeit von Geldgebern aus den USA. Die industrielle Wertschöpfung werde so dauerhaft in Ausland abwandern.https://www.handelsblatt.com/unternehmen/industrie/interview-biotech-investor-struengmann-in-deutschland-haetten-wir-null-chancen-gehabt/25300520.html?ticket=ST-10587898-e4sRfYRA9XreKtXzGt9D-ap2&utm_term=Autofeed&social=tw-hb_hk-li-ne-or-&utm_medium=Social&utm_content=hb_hk&utm_source=Twitter#Echobox=1575548907 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Very interesting article about the coming age of
#biosimilars. It is estimated that by 2025 biosimilars will reach a worldwide market value of over $61 Billion. The coming age of biosimilars | Pharmafile http://www.pharmafile.com/news/534263/coming-age-biosimilars#.XeTc6X61-ZQ.twitter …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A joint report has been issued by the European Commission (EC) and the UK Organisation for Economic Co-operation and Development (OECD) on
#healthcare in the EU, highlighting the importance of generics and#biosimilars for HealthCare Systems.https://www.europeanpharmaceuticalreview.com/news/107026/generics-and-biosimilars-vital-to-reduce-healthcare-costs-finds-ec/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon is looking forward to present financial figures and corporate developments to
#analysts,#investors and#journalists at#EKF19 on November 26 at#Frankfurt https://www.eigenkapitalforum.com/#/de/ pic.twitter.com/1niH5umgBb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This is exactly what
#biosimilars are supposed to do: Enabling broad#acces to high#quality and highly#competitive#biopharmaceuticals for the treatment of serious#diseases.https://probiosimilars.de/presse/grafik-des-monats-november-4/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Formycon Reports Its Nine-Month Figures For 2019https://www.formycon.com/en/news-media/press-releases/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Impressive Forecast: U.S.
#Biosimilar market is projected to reach around USD 17 Billion in 2026https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@formycon appreciates that Bioeq IP AG, the exclusive owner of the global commercialization rights of#FYB201, has signed a license and development agreement with Coherus BioSciences, Inc. to market and distribute#Formycon's ´#biosimilar candidate to#Lucentis (FYB201) in the UShttps://twitter.com/BiosimCenter/status/1192472184297545730 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@Formycon ist happy to announce that#Bioeq IP AG exclusively#licenses#US Marketing Rights for#FYB201 to Coherus BioSciences, Inc. We consider@Coherus_Bio as a strong and competent#partner for a successful#commercialization of FYB201 in the US.https://www.formycon.com/en/press-release/bioeq-ip-ag-exclusively-licenses-us-marketing-rights-for-fyb201-to-coherus-biosciences-inc/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.